Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
Immunovant (Nasdaq: IMVT) will report its second fiscal quarter financial results before the market opens on November 9, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immunovant (Nasdaq: IMVT) will report its second fiscal quarter financial results before the market opens on November 9, 2026.
The quarter ended September 30, 2026. Majority stockholder Roivant Sciences (Nasdaq: ROIV) will host a conference call and webcast at 8:00 a.m. ET that day, including an Immunovant business update. An archived webcast will be available on Immunovant’s website afterward.
Details
Market Reaction – ROIV
On Oct 21, the day this news came out, the latest delayed price for ROIV is 9.48% above the previous close. Our momentum scanner has recorded 8 alerts for this stock so far that day. The latest delayed price is $38.23. Relative volume is exceptionally heavy at 35.8x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Results reporting date
- November 9, 2026
- Second fiscal quarter results scheduled before market open
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the second fiscal quarter ended September 30, 2026 on Monday, November 9, 2026 before the market opens. Roivant Sciences Ltd. (Nasdaq: ROIV), Immunovant’s majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that same day, which will include a business update for Immunovant.
To access the Roivant conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “News & Events” in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant’s website after the conference call.
About Immunovant
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases and is a majority-owned subsidiary of Roivant. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.
Contacts:
Investors
Keyur Parekh
keyur.parekh@roivant.com
Media
Stephanie Lee
stephanie.lee@roivant.com
